A Phase II Study of Cs-131 Brachytherapy for People with Brain Metastases that Have Recurred


Full Title

Intracavitary Cs131 Brachytherapy for Recurrent Brain Metastases: A Randomized Phase II Study


The purpose of this study is to evaluate the safety and effectiveness of cesium-131 (Cs-131) brachytherapy in patients with brain cancer that has come back after prior radiation therapy and who will be having surgery to remove it. Brachytherapy involves the placement of radioactive seeds into the brain during surgery. The seeds remain in place permanently in the area where the tumor was removed and give off cancer-killing radiation temporarily. 

Doctors hope that using Cs-131 brachytherapy in addition to surgery is more effective than surgery alone for preventing brain tumors from growing back after surgery. Patients in this study will be randomly assigned to undergo brain tumor surgery with or without brachytherapy.

Who Can Join

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have metastatic brain cancer that has come back after prior radiation therapy and can be surgically removed.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Nelson Moss at 212-639-7075.




Phase II (phase 2)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID